证券代码：688607 证券简称：康众医疗 公告编号：2025-036 江苏康众数字医疗科技股份有限公司 关于 2025 年提质增效重回报行动方案 半年度评估报告的公告 江苏康众数字医疗科技股份有限公司（以下简称"康众医疗"或"公司"） 为践行"以投资者为本"的发展理念，维护公司及全体股东利益，基于对公司未 来发展前景的信心，公司于 2025 年 4 月 26 日披露了《关于 2024 年度提质增效 重回报行动方案评估报告暨 2025 年度提质增效重回报行动方案》 （以下简称"行 动方案"）。2025 年上半年度，公司切实履行并持续评估行动方案的具体举措， 现将行动方案的实施效果和 2025 上半年度执行情况的评估报告如下： 一、聚集主营业务，推动企业高质量发展 全面把握国内经济稳步复苏机遇，全面推动经营业务长远稳定发展、不断增强公 司核心竞争力。报告期内，公司实现营业收入 144,883,131.24 元，较上年同期增 长 12.41%，归属于上市公司股东的净利润为-739,398.63 元，因对应收账款计提 坏账准备，导致较上年同期有所减少。2025 年上半年度，公司管理层及全体员 工坚持加快战略推进、技 ...

Core Insights - The report highlights the significant growth in revenue and profitability for various companies in the technology and energy sectors, indicating a positive trend in their respective markets [6][23][15]. Industry Overview - The non-bank financial sector is experiencing a resurgence, with a focus on investment value as half-year reports are being released [5]. - The semiconductor and advanced packaging industries are seeing increased demand, driven by technological advancements and market expansion [8][11]. Company Analysis - **Stone Technology (688169.SH)**: The company reported a revenue of 7.903 billion, a year-on-year increase of 78.96%, but a decline in net profit by 39.55% [6]. - **Jiaocheng Ultrasonic (688392.SH)**: The company experienced a significant improvement in profitability, with a focus on scaling its advanced packaging business [8]. - **Green's Harmonics (688017.SH)**: The company achieved a revenue growth of 45.8% in the first half of 2025, driven by a recovery in the industrial robot market [15]. - **Hongyuan Co., Ltd. (920018.BJ)**: Recognized as a national champion in the electromagnetic wire industry, the company is leveraging its advantages in the ultra-high voltage sector [14]. - **JianTou Energy (000600.SZ)**: The company reported a substantial increase in net profit by 169.37% in the first half of 2025, attributed to effective cost management and stable power generation performance [23][24]. Financial Performance - **Stone Technology**: The company’s H1 revenue reached 7.903 billion, with a net profit of 678 million, reflecting a significant year-on-year revenue increase [6]. - **Jiaocheng Ultrasonic**: The company’s H1 gross margin was 44.56%, with a net margin of 8.57%, indicating improved profitability [8]. - **Green's Harmonics**: The company’s Q2 revenue grew by 69.5%, with a net profit increase of 101% [15]. - **JianTou Energy**: The company’s H1 revenue was 111.13 billion, with a net profit of 8.97 billion, showcasing strong financial health [23]. Investment Recommendations - The report suggests a "Buy-A" rating for companies like Stone Technology and Jiaocheng Ultrasonic, indicating strong future growth potential [8][11]. - JianTou Energy is also recommended for investment due to its robust financial performance and strategic project developments [23][26].

Investment Rating - The report maintains a "Recommended" rating for the company, indicating a potential upside of over 15% relative to the benchmark index [6][12]. Core Insights - The company achieved a revenue of 1.067 billion yuan in H1 2025, representing a year-on-year increase of 3.94%, and a net profit attributable to shareholders of 335 million yuan, up 8.82% year-on-year [1]. - The company's gross margin was 52.97%, with a slight year-on-year decrease of 1.18 percentage points, while the net profit margin improved by 1.20 percentage points to 30.47% [2]. - The company is expected to benefit from the medical equipment upgrade policy, with projected revenues of 2.29 billion, 3.02 billion, and 3.83 billion yuan for 2025, 2026, and 2027 respectively, alongside net profits of 627 million, 851 million, and 1.053 billion yuan [4]. Financial Performance Summary - In H1 2025, the company's revenue from the detector business was 866 million yuan, a year-on-year increase of 2.65%, while the core components business generated 82 million yuan in revenue with a gross margin of 18.2% [2]. - The company invested 154 million yuan in R&D in H1 2025, representing a R&D expense ratio of 14.46% [2]. - The company forecasts a net profit growth rate of 34.9% for 2025, with an expected PE ratio of 34 [5][10].

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative increase of over 15% in the stock price within the next 6 to 12 months [16]. Core Viewpoints - The company has shown a recovery in performance with a 3.94% year-on-year increase in revenue for the first half of 2025, reaching 1.067 billion yuan, and an 8.82% increase in net profit attributable to shareholders, totaling 335 million yuan [4][5]. - The second quarter of 2025 saw a significant revenue growth of 9.32% year-on-year, amounting to 585 million yuan, alongside a 13.86% increase in net profit attributable to shareholders [4][5]. - The company is positioned as a leader in the domestic X-ray detector market, with a global market share of 19.83% projected for 2024, up from 16.46% in 2021 [11]. - The company is expanding its production capacity for silicon-based OLED backplanes and has received regulatory approval for a capital increase to fund new product development [12]. Summary by Sections Financial Performance - In the first half of 2025, the company achieved a revenue of 1.067 billion yuan, with a net profit of 335 million yuan, reflecting a year-on-year growth of 3.94% and 8.82% respectively [4]. - The second quarter of 2025 reported a revenue of 585 million yuan, a 9.32% increase year-on-year, and a net profit of 191 million yuan, up 13.86% [4][5]. Growth Drivers - The recovery in revenue growth is attributed to several factors, including the domestic medical equipment replacement policy, partnerships with leading dental equipment manufacturers, and increased demand from lithium battery manufacturers [6]. - The company has seen significant growth in new core components and solutions, with some areas experiencing over 50% year-on-year growth [6]. Profitability Analysis - The gross profit margin for the second quarter of 2025 was 56.31%, an increase of 1.40 percentage points year-on-year, while the net profit margin rose to 32.36%, up 1.86 percentage points [7]. - The company’s operating cash flow showed a substantial recovery, with a net cash flow from operating activities of 818 million yuan, a year-on-year increase of 340.20% [8]. Research and Development - The company continues to invest in R&D, with expenses amounting to 154 million yuan in the first half of 2025, representing 14.46% of revenue [9]. - The company has filed 28 new intellectual property applications in the first half of 2025, including 14 invention patents [9]. Market Position and Expansion - The global X-ray core component market is expected to grow significantly, with projections indicating a market size exceeding 50 billion USD by 2030 [10]. - The company is expanding its production capacity for silicon-based OLED backplanes and has plans for new product development, which is expected to enhance its competitive edge [12].

Core Business Expansion and Competitiveness Enhancement - The company is a digital X-ray core component and comprehensive solution supplier, focusing on R&D, production, sales, and services of digital X-ray detectors, high-voltage generators, and other core components [1] - The company has established a global layout with six production bases, including new facilities in Haining, Taicang, and Cleveland, enhancing its competitive edge [1] - In the first half of 2025, overseas revenue reached 366 million yuan, accounting for approximately 34% of total revenue, indicating a continuous increase in overseas business [1] Investment in New Projects - The company plans to invest up to 1.8 billion yuan in a silicon-based OLED microdisplay backplane production project, which will add a capacity of 5,000 units per month [2] - This investment is expected to enhance the company's technological innovation and strengthen its core competitiveness [2] R&D Innovation and High-Quality Development - The company invested 154.24 million yuan in R&D, representing 14.46% of its revenue, and registered 70 new IPs, including 32 invention patents [2] - Ongoing projects include the development of key technologies for digital X-ray detectors and the establishment of an innovation base [2][3] Governance and Operational Standards - The company has established a governance structure with clear responsibilities among the shareholders' meeting, board of directors, supervisory board, and management [4] - The company held multiple board meetings and complied with legal and regulatory requirements for governance [5] Shareholder Returns and Value Sharing - In June 2025, the company completed its 2024 annual equity distribution, distributing cash dividends of 10 yuan per 10 shares and a stock bonus of 4 shares per 10 shares, totaling 142.89 million yuan in cash dividends [6] ESG Commitment and Sustainable Development - The company integrates ESG principles into its strategy and operations, focusing on innovation and quality management to contribute to human health [7] - A report detailing the company's practices in environmental protection and social responsibility is available on the Shanghai Stock Exchange website [7] Future Plans - The company will continue to focus on digital X-ray core components and solutions, enhance governance structures, and improve risk management to achieve high-quality development [8]

Investment Rating - The report maintains a "Buy" rating for the company [6][20]. Core Views - The company is a leading global supplier of X-ray core components and solutions, with a diversified downstream distribution. The recovery in downstream medical, dental, and industrial sectors since 2025 is promising, and new products like CT tubes and silicon-based OLED microdisplay backplanes are expected to have significant growth potential [1][2]. - The company has announced an investment of up to RMB 1.8 billion for a silicon-based OLED microdisplay backplane production project, which is anticipated to add a capacity of 5,000 units per month [3][15]. - There is substantial domestic replacement potential for core components like CT tubes, with an estimated market space of RMB 1 to 5 billion due to the ongoing anti-dumping investigations against imports from the US and India [4][20]. Summary by Sections Financial Performance - The company expects a revenue decline of 2% in 2024, primarily due to poor downstream conditions, but anticipates a recovery in 2025 with a projected revenue increase of 17.18% [2][10]. - The forecasted net profit for 2025-2027 is RMB 5.9 billion, RMB 8.5 billion, and RMB 11.0 billion, representing year-on-year growth rates of 26%, 46%, and 29% respectively [5][19]. Revenue Breakdown - The detector segment is expected to grow at rates of 16%, 19%, and 19% from 2025 to 2027, with a recovery in demand from the medical and dental sectors [12][17]. - The core components segment is projected to see revenue growth of 43%, 39%, and 28% over the same period, driven by advancements in high-voltage generators and ray sources [13][17]. - The solutions and technical services segment is anticipated to grow significantly, with expected revenues of RMB 350 million, RMB 500 million, and RMB 700 million from 2025 to 2027 [14][17]. Valuation - The target price for the company is set at RMB 132, based on a price-to-earnings (PE) ratio of 45 times for 2025, reflecting a significant adjustment from previous estimates due to overall market conditions [5][20]. - The company's market capitalization is approximately RMB 17.36 billion, with a closing price of RMB 86.70 as of July 2, 2025 [7][10].

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [5] Core Views - The company experienced a revenue of 1.83 billion yuan in 2024, a year-over-year decrease of 1.7%, and a net profit attributable to shareholders of 470 million yuan, down 23.4% year-over-year. In Q1 2025, the revenue was 480 million yuan, a decrease of 1.9% year-over-year, while the net profit attributable to shareholders was 140 million yuan, an increase of 2.7% year-over-year [1][2] Performance Summary - In 2024, the company faced pressure on performance due to a slowdown in bidding and fluctuations in demand for new energy testing. However, the company is in a strategic upgrade phase, with ongoing construction projects expected to enhance long-term growth potential. The company is transitioning from a flat detector supplier to a comprehensive imaging solution provider, indicating strong medium to long-term investment value [2][4] - The company launched new medical products, including a 64-row medical CT detector module, and high-end DSA detectors have entered mass production. The new core component business generated revenue of 126 million yuan in 2024, a year-over-year increase of 45.5%, while the comprehensive solutions and technical services business achieved revenue of 86.8 million yuan, a year-over-year increase of 226.3% [2][3] Growth Potential - The company has established overseas sales or customer service platforms in various countries, including the USA, Germany, South Korea, India, Japan, Mexico, Pakistan, Brazil, and South Africa. The company has seen positive growth from major customers, with dental products achieving small batch sales overseas and industrial core components performing well, generating nearly 100 million yuan in revenue [4] - The company is expected to see a gradual recovery in gross margin and a decrease in operating expense ratios as low-margin new products scale up. The operating cash flow for 2024 was 360 million yuan, a year-over-year increase of 5.9% [9][10] Financial Forecasts - The company forecasts revenues of 2.23 billion yuan in 2025, representing a year-over-year growth of 22.01%, and a net profit attributable to shareholders of 599 million yuan, an increase of 28.67% year-over-year. The expected EPS for 2025 is 4.18 yuan, with a current price-to-earnings ratio of 29.7 times [10][12]

Investment Rating - The investment rating for the company is "Outperform the Market" [5][27]. Core Views - The company's revenue for 2024 decreased by 1.74% year-on-year to 1.831 billion yuan, and the net profit attributable to the parent company decreased by 23.43% to 465 million yuan. However, the first quarter of 2025 showed signs of stabilization with a net profit increase of 2.74% year-on-year [1][5]. - The detector business remains under pressure due to weak downstream demand, but the company is actively expanding its overseas market and enhancing customer cooperation to maintain its leading global market share [3][5]. - New core components and solutions have completed their layout and are entering a rapid growth phase, with significant revenue increases expected in the coming years [4][5]. Financial Performance Summary - In 2024, the company's gross margin was 50.11%, down 7.73 percentage points year-on-year, primarily due to an increase in the proportion of low-margin non-detector businesses. The net margin was 24.59%, down 7.86 percentage points [2][5]. - The first quarter of 2025 saw a gross margin of 48.92% and a net margin of 28.17%, indicating a slight recovery in profitability [2][5]. - The company expects revenue growth of 19.12% in 2025, reaching 2.181 billion yuan, with net profit projected to increase by 27.5% to 593 million yuan [25][26]. Business Segment Performance - The detector segment generated revenue of 1.49 billion yuan in 2024, a decrease of 11.99% year-on-year, with a gross margin of 56.65% [3][23]. - The new core components segment achieved revenue of 126 million yuan in 2024, growing by 45.49%, while the solutions and technical services segment saw a remarkable increase of 262.56% to 96 million yuan [4][23]. - The company is focusing on expanding its product lines and application areas, particularly in the medical and industrial fields, which are expected to drive future growth [5][21].

Investment Rating - The investment rating for the company is "Outperform the Market" [5][27]. Core Views - The company's revenue for 2024 decreased by 1.74% year-on-year to 1.831 billion yuan, and the net profit attributable to the parent company decreased by 23.43% to 465 million yuan. However, in the first quarter of 2025, the company achieved a revenue of 482 million yuan, a year-on-year decrease of 1.92%, while the net profit attributable to the parent company increased by 2.74% to 143 million yuan, indicating a stabilization in performance [1][5]. - The detector business faced short-term pressure due to weak downstream demand, but the company is actively expanding overseas markets and enhancing customer cooperation, which is expected to improve market share [3][5]. - The new core components and solutions have completed their layout and are entering a rapid growth phase, with significant revenue growth in these segments [4][5]. Financial Performance Summary - In 2024, the company's gross margin was 50.11%, down 7.73 percentage points year-on-year, primarily due to an increase in the proportion of low-margin non-detector businesses. The net margin was 24.59%, down 7.86 percentage points year-on-year [2]. - The company expects to achieve net profits of 593 million yuan, 707 million yuan, and 878 million yuan for 2025, 2026, and 2027, respectively, reflecting a growth of 27.5%, 19.2%, and 24.2% year-on-year [25][26]. Revenue Breakdown - The revenue from the detector business in 2024 was 1.49 billion yuan, a decrease of 11.99% year-on-year, while the revenue from new core components was 126 million yuan, up 45.49% year-on-year. The solutions and technical services segment saw a revenue increase of 262.56% to 96 million yuan [3][4][23]. - The company anticipates that the detector business will recover with expected growth rates of 15% for 2025-2027, while the solutions and technical services segment is projected to grow at rates of 65.87%, 50%, and 50% for the same period [20][21].

Investment Rating - The report maintains an "Outperform" rating for the company [1][10]. Core Insights - In 2024, the company achieved revenue of RMB 1.83 billion, a decrease of 1.74%, with a net profit attributable to shareholders of RMB 465 million, down 23.43%. For Q1 2025, revenue was RMB 482 million, a decline of 1.92%, while net profit increased by 2.74% to RMB 143 million [10][11]. - The company has revised its EPS forecasts for 2025 and 2026 to RMB 4.07 and RMB 5.02, respectively, and introduced a new forecast for 2027 at RMB 6.22. The target price is set at RMB 143.10, corresponding to a 2025 PE of 35X [10][12]. Financial Summary - The company's revenue for 2024 is projected at RMB 2.22 billion, with a growth rate of 21.0% in 2025 and 22.0% in 2026. The net profit is expected to recover to RMB 583 million in 2025, with further growth anticipated in subsequent years [4][6]. - The company’s market share in the global digital X-ray detector industry reached 20.09% in 2023, indicating a solidified market position despite a decrease in sales revenue for detectors in 2024 [11][12]. Business Growth and Development - The new core components business saw a revenue increase of 45.49% in 2024, while integrated solutions and technical services revenue surged by 226.25% [12][13]. - The company is actively expanding its domestic and international markets, establishing sales and service platforms in various countries, including the USA, Germany, and India, which contributed to nearly RMB 100 million in revenue from new core components and solutions [13][12].